Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Soficabtagene geleucel - Allotera Therapeutics

Next Previous
Drug Profile

Soficabtagene geleucel - Allotera Therapeutics

Alternative Names: Allogenic CAR-T cell therapies - Allotera Therapeutics; Anti-CD7 Allogeneic CAR T Cells - Allotera Therapeutics; WU-007; WU-CART-007

Latest Information Update: 31 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator WUGEN
  • Developer Allotera Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor T-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase I Haematological malignancies

Most Recent Events

  • 21 Jul 2026 Wugen suspends phase I trial in Haematological malignancies (Second-line therapy or greater) in the US(NCT05377827)
  • 08 Jul 2026 WUGEN is now called Allotera Therapeutics
  • 21 Jan 2026 Soficabtagene geleucel - Wugen receives Breakthrough Therapy status for Precursor cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top